-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Aardvark Therapeutics with Buy Rating, Announces Price Target of $40

Benzinga·06/30/2025 11:04:45
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Aardvark Therapeutics (NASDAQ:AARD) with a Buy rating and announces Price Target of $40.